Everything below concerns certificate of analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Because these enzyme levels are not elevated immediately following a heart attack, patients presenting with chest pain are generally treated with the assumption that a myocardial infarction has occurred and then evaluated for a more precise diagnosis.
Because the decretal did not end all controversy and some bishops did not obey it in so far as it regarded beatification, the right of which they had certainly possessed hitherto, Urban VIII published a papal bull in 1634 which ended all discussion by exclusively reserving to the Apostolic See both the right of canonization and that of beatification.
An examination using human cells in-vitro displayed gingerols capabilities in combating oxidative stress. The results concluded that gingerol had anti-inflammatory effects though shogaol showed the most promising effects combating free radicals. There was an inverted dose- concentration response and as dosage concentration increased the amount of free radicals in cells decreased. Cisplatin is a chemotherapy drug that if used in high dosages causes renal failure which is considered a limiting factor for this life saving drug. By using [6]-gingerol it prevented the occurrence of renal failure in rats. [6]-gingerol improved glutathione production in dose-dependent results which suggested that the higher a dosage the more of an effect [6]-gingerol had. Gingerol compounds are thought to help in diabetic patients because of increases in glutathione, a cellular toxin regulatory factor. Anti-hyperglycaemic effects were studied in diabetic and severely obese mice. Gingerol compounds increased glucose uptake in cells without the need of a synthetic insulin activator, while also decreasing fasting glucose and increasing glucose tolerance. In a different study the exact metabolic mechanisms associated with the physiological benefits of gingerol phytochemicals concluded that there was increased enzyme activity (CAT) and glutathione production while decreasing lipoprotein cholesterol and improving glucose tolerance in mice.
The September 11 attacks introduced foreign terrorism as a major security issue to the U.S., as they indicated smaller states and terrorist organizations had become increasingly capable even against major global powers. Many governments across the world passed legislation to combat terrorism as a result to the attacks. In Germany, where several of the 9/11 terrorists had resided and taken advantage of that country's liberal asylum policies, two major anti-terrorism packages were enacted. The first removed legal loopholes that permitted terrorists to live and raise money in Germany. The second addressed the effectiveness and communication of intelligence and law enforcement. Canada passed the Canadian Anti-Terrorism Act, their first anti-terrorism law. The United Kingdom passed the Anti-terrorism, Crime and Security Act 2001 and the Prevention of Terrorism Act 2005. New Zealand enacted the Terrorism Suppression Act 2002. In the United States, the Department of Homeland Security was created by the Homeland Security Act of 2002 to coordinate domestic anti-terrorism efforts. The USA Patriot Act gave the federal government greater powers, including the authority to detain foreign terror suspects for a week without charge; to monitor terror suspects' telephone communications, e-mail, and Internet use; and to prosecute suspected terrorists without time restrictions. The FAA ordered that airplane cockpits be reinforced with a secondary flight deck to prevent terrorists from gaining control of planes and assigned sky marshals to flights.
Sources: en.wikipedia.org
== Effectiveness == A landmark randomized placebo control trial on NASHA Dx was published in 2011 in the Lancet. 136 were given real injections and 70 patients were given shame (fake) injections. 80% of the patients had no improvement 1 month after the procedure, and were given a second injection. After 6 months, 52% of patients who received real injections had improved symptoms. However, the patients who received fake injections reported over 30% improvement in symptoms, suggesting that patient psychology (i.e. the placebo effect) may be in part responsible for any positive results. 6% of patients who received real injections were fully continent after 6 months. After publication of this study, the material was approved by the FDA in the USA in 2012. The material was aggressively marketed, and became popular for a time because of its potential as an in office treatment with low risks compared to other surgical options. However uncertainty about indications, cost, and long term durability stopped widespread adoption. A Cochrane systematic review of the efficacy of this type of treatment for FI was updated in 2013. The review included 5 randomized trials, which in total was 382 patients. 4 of the trials were assessed as uncertain or high risk of bias. Another commentator drew attention to the fact that all existing research on these procedures was driven by the companies who also marketed the treatments, and therefore the studies are indeed at high risk of bias.
The teeth differed slightly (they were heterodont) based on position: those near the tips of the upper jaws (on the premaxillae) were slender and lacked serrations, while those behind them (on the maxillae) were serrated and laterally compressed. The teeth of the lower jaws were similarly differentiated. A pigmented area in the abdomen of the holotype has been suggested as possible traces of organs, and was interpreted as the liver by John Ruben and colleagues, which they described as part of a crocodilian-like "hepatic piston" respiratory system. A later study, while agreeing that the pigmented area represented something originally inside the body, found no defined structure and noted that any organs would have been distorted by the processes that flattened the skeleton into an essentially two-dimensional form. Dark pigment is also present in the eye region of the holotype and another specimen.
Collagen alpha-1(XIII) chain is a protein that in humans is encoded by the COL13A1 gene. This gene encodes the alpha chain of one of the nonfibrillar collagens. The function of this gene product is not known, however, it has been detected at low levels in all connective tissue-producing cells so it may serve a general function in connective tissues. Unlike most of the collagens, which are secreted into the extracellular matrix, collagen XIII contains a transmembrane domain and the protein has been localized to the plasma membrane. The transcripts for this gene undergo complex and extensive splicing involving at least eight exons. Like other collagens, collagen XIII is a trimer; it is not known whether this trimer is composed of one or more than one alpha chain isomer. A number of alternatively spliced transcript variants have been described, but the full length nature of some of them has not been determined. Collagen XIII belongs to the transmembranous subfamily of collagens, like collagen XVII, XXIII and XXV.
Krypton (from Ancient Greek: κρυπτός, romanized: kryptos 'the hidden one') is a chemical element; it has symbol Kr and atomic number 36. It is a colorless, odorless noble gas that occurs in trace amounts in the atmosphere and is often used with other rare gases in fluorescent lamps. Krypton is chemically inert. Krypton, like the other noble gases, is used in lighting and photography. Krypton light has many spectral lines, and krypton plasma is useful in bright, high-powered gas lasers (krypton ion and excimer lasers), each of which resonates and amplifies a single spectral line. Krypton fluoride also makes a useful laser medium. From 1960 to 1983, the official definition of the metre was based on the wavelength of one spectral line of krypton-86, because of the high power and relative ease of operation of krypton discharge tubes.
Russell and Norvig agree with Turing that intelligence must be defined in terms of external behaviour, not internal structure. However, they are critical that the test requires the machine to imitate humans. "Aeronautical engineering texts", they wrote, "do not define the goal of their field as making 'machines that fly so exactly like pigeons that they can fool other pigeons.'" AI founder John McCarthy agreed, writing that "Artificial intelligence is not, by definition, simulation of human intelligence". McCarthy defines intelligence as "the computational part of the ability to achieve goals in the world". Another AI founder, Marvin Minsky, similarly describes it as "the ability to solve hard problems". Artificial Intelligence: A Modern Approach defines it as the study of agents that perceive their environment and take actions that maximise their chances of achieving defined goals. The many differing definitions of AI have been critically analysed. During the 2020s AI boom, the term has been used as a marketing buzzword to promote products and services which do not use AI.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
Dry lyophilized powder is usually kept frozen, desiccated, and out of direct light. Sealed vials are not opened until needed, because moisture uptake can degrade short peptides. Longer archival storage is often done at lower temperatures than routine working stock.